Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3108230 | 0.90 | ESR1 (0.48) | TRPV1ESR1ESR2SLC6A9 | |
| SCHEMBL3108816 | 0.89 | TRPV1 (0.50) | TRPV1ESR1ESR2SLC6A9 | |
| SCHEMBL3100814 | 0.88 | TRPV1 (0.49) | TRPV1ESR1ESR2SLC6A9DRD3 | |
| SCHEMBL605986 | 0.88 | TRPV1 (0.42) | TRPV1ESR1ESR2SLC6A9 | |
| SCHEMBL9490339 | 0.86 | TRPV1 (0.57) | TRPV1SLC6A9 | |
| SCHEMBL3094360 | 0.86 | SLC6A9 (0.50) | TRPV1SLC6A9 | |
| SCHEMBL14957372 | 0.86 | TRPV1 (0.47) | TRPV1ESR1ESR2SLC6A9 | |
| SCHEMBL14957700 | 0.86 | TRPV1 (0.47) | TRPV1ESR1ESR2SLC6A9 | |
| SCHEMBL3101263 | 0.85 | ESR1 (0.43) | TRPV1ESR1ESR2SLC6A9 | |
| SCHEMBL14962077 | 0.85 | TRPV1 (0.49) | TRPV1ESR1ESR2SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846741-B2 | N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2780328-A1 | N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbvie Deutschland GmbH & Co. KG (DE) | 2014-09-24 | — | — | EP | disclosed |
| US-20130131132-A1 | N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013072520-A1 | N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131132-A1 | N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AADAT, BCAT1, NMT1 | TRPV1 1024/4885ESR1 4191/4885ESR2 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.